Related Categories: APIs; pharmaceutical intermediates; protein tyrosine kinases; pharmaceutical impurities; small molecule inhibitors, natural products; imatinib intermediates;
Nature
Melting point | 208-210°C (dec.) |
Storage conditions | Refrigerator |
Acidity coefficient (pKa) | pKa1 8.07; pKa2 3.73; pKa3 2.56; pKa4 1.52(at 25℃) |
Merck | 14,4902 |
CAS database | 152459-95-5(CAS DataBase Reference) |
product description
Imatinib is an oral drug used in the treatment of adult patients with chronic myeloid leukemia (CML) who are positive for Ber-Abl (CML), acute phase, and chronic phase after failure of interferon therapy. . CML is a hematopoietic stem cell disease caused by DNA abnormalities in stem cells in the bone marrow. Abnormal DNA produces abnormal proteins that interfere with the normal process of white blood cell formation in the bone marrow, which ultimately leads to a dramatic increase in the number of white blood cells. CML is divided into three stages: chronic phase, accelerated phase and crisis phase. The average survival elbow of patients in crisis is only 2-3 months.
Imatinib is also effective in the treatment of gastrointestinal stromal tumors, with an effective rate of about 50%.
Use
Oral medication for the treatment of adult patients with chronic myelogenous leukemia of Ber-Abl-positive chronic myeloid leukemia, accelerated phase, and chronic phase after failure of interferon therapy
After 26 years business done, we have excellent knowledge in the Chinese market. We provide the best price/quality ratio to satisfy requirements of global market.
dlsky@dlskychem.com
+86-411-86487833
